DE69942708D1 - Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten - Google Patents

Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten

Info

Publication number
DE69942708D1
DE69942708D1 DE69942708T DE69942708T DE69942708D1 DE 69942708 D1 DE69942708 D1 DE 69942708D1 DE 69942708 T DE69942708 T DE 69942708T DE 69942708 T DE69942708 T DE 69942708T DE 69942708 D1 DE69942708 D1 DE 69942708D1
Authority
DE
Germany
Prior art keywords
virus
concentration
methods
containing compositions
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942708T
Other languages
English (en)
Inventor
Andreas Frei
Henry K H Kwan
Varda E Sandweiss
Gary J Vellekamp
Pui-Ho Yuen
Laureano L Bondoc Jr
Frederick William Porter Iv
John Chu-Tay Tang
Peter Ihnat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE69942708D1 publication Critical patent/DE69942708D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69942708T 1998-02-17 1999-02-12 Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten Expired - Lifetime DE69942708D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US7964398A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
DE69942708D1 true DE69942708D1 (de) 2010-10-07

Family

ID=26698472

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69936948T Expired - Lifetime DE69936948T2 (de) 1998-02-17 1999-02-12 Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
DE69942708T Expired - Lifetime DE69942708D1 (de) 1998-02-17 1999-02-12 Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
DE69933433T Expired - Lifetime DE69933433T2 (de) 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69936948T Expired - Lifetime DE69936948T2 (de) 1998-02-17 1999-02-12 Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69933433T Expired - Lifetime DE69933433T2 (de) 1998-02-17 1999-02-12 Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten

Country Status (25)

Country Link
EP (4) EP1526174B1 (de)
JP (3) JP4358434B2 (de)
KR (5) KR100918187B1 (de)
CN (2) CN101164623B (de)
AR (3) AR020054A1 (de)
AT (3) ATE371020T1 (de)
AU (1) AU757976B2 (de)
BR (1) BR9908015A (de)
CA (2) CA2320419C (de)
CO (1) CO4820440A1 (de)
DE (3) DE69936948T2 (de)
DK (1) DK1054955T3 (de)
ES (2) ES2272053T3 (de)
HK (3) HK1028416A1 (de)
HU (1) HU226015B1 (de)
ID (1) ID28298A (de)
IL (2) IL137510A0 (de)
MY (1) MY141641A (de)
NO (1) NO20004104L (de)
PE (1) PE20000265A1 (de)
PL (1) PL197747B1 (de)
PT (1) PT1054955E (de)
SK (1) SK11842000A3 (de)
TW (1) TWI232107B (de)
WO (1) WO1999041416A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
ATE348155T1 (de) 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
WO2000029024A1 (en) * 1998-11-16 2000-05-25 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2001066137A1 (en) * 2000-03-07 2001-09-13 Merck & Co., Inc. Adenovirus formulations
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
JP2002241311A (ja) * 2000-12-12 2002-08-28 Japan Tobacco Inc 界面活性剤を含む医薬組成物
JP2005517394A (ja) 2001-12-12 2005-06-16 エフ エイチ フォールディング アンド カンパニー リミテッド ウイルス保存のための組成物
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
EP1465664A1 (de) * 2002-01-18 2004-10-13 Schering Aktiengesellschaft Stabilisierte formulierungen von adenovirus
NZ548495A (en) 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
KR20070104339A (ko) 2004-11-03 2007-10-25 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터의 생산과 정제를 위한 신규한 방법
ATE516343T1 (de) 2004-12-13 2011-07-15 Canji Inc Zellinien zur produktion von replikationsdefektem adenovirus
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
US20070249043A1 (en) 2005-12-12 2007-10-25 Mayall Timothy P Adenoviral expression vectors
MX2008013494A (es) * 2006-04-20 2009-01-26 Wyeth Corp Procesos de purificacion para aislar virus puirificado de la estomatitis vesicular provenientes de cultivo celular.
JP5770633B2 (ja) 2008-11-03 2015-08-26 クルセル ホランド ベー ヴェー アデノウイルスベクターの産生方法
RU2603740C2 (ru) 2009-05-02 2016-11-27 Джензим Корпорейшн Генная терапия нейродегенеративных нарушений
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
SG190418A1 (en) 2010-12-02 2013-07-31 Oncolytics Biotech Inc Liquid viral formulations
ES2630012T3 (es) 2010-12-02 2017-08-17 Oncolytics Biotech Inc. Formulaciones virales liofilizadas
DK2702147T3 (da) * 2011-04-29 2020-09-28 Oncolytics Biotech Inc Fremgangsmåder til oprensning af vira ved hjælp af gelpermeationskromatografi
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CN104334188B (zh) 2012-03-22 2016-08-24 克鲁塞尔荷兰公司 抗rsv疫苗
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
AP2015008893A0 (en) 2013-06-17 2015-12-31 Crucell Holland Bv Stabilized soluble pre-fusion rsv f polypeptides
US10280195B2 (en) * 2014-05-28 2019-05-07 Agency For Science, Technology And Research Virus reduction method
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
ES2858315T3 (es) 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
PE20190433A1 (es) 2016-04-05 2019-03-21 Janssen Vaccines And Prevention B V Vacuna contra vrs
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
MX2018015540A (es) 2016-06-20 2019-04-11 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
JP2022539148A (ja) * 2019-06-28 2022-09-07 武田薬品工業株式会社 アデノ随伴ウイルスの精製方法
WO2021155323A1 (en) 2020-01-31 2021-08-05 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines
JP2024509756A (ja) 2021-02-19 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前ｒｓｖ ｆｂ抗原
WO2023020556A1 (zh) * 2021-08-17 2023-02-23 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (de) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
CN1263864C (zh) 1993-10-25 2006-07-12 坎吉公司 重组腺病毒载体及其使用方法
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
CO4820440A1 (es) 1999-07-28
JP4358434B2 (ja) 2009-11-04
KR101018992B1 (ko) 2011-03-07
HUP0100670A3 (en) 2003-10-28
CN1297478A (zh) 2001-05-30
ES2290613T3 (es) 2008-02-16
KR100862169B1 (ko) 2008-10-09
IL137510A (en) 2012-10-31
EP1741777B1 (de) 2010-08-25
CA2320419A1 (en) 1999-08-19
ID28298A (id) 2001-05-10
WO1999041416A3 (en) 1999-11-18
WO1999041416A2 (en) 1999-08-19
DK1054955T3 (da) 2007-01-15
HUP0100670A2 (hu) 2001-06-28
CA2723040A1 (en) 1999-08-19
KR20010072547A (ko) 2001-07-31
CN101164623B (zh) 2012-11-14
EP1526174A3 (de) 2005-08-31
DE69933433T2 (de) 2007-08-23
MY141641A (en) 2010-05-31
KR20080065614A (ko) 2008-07-14
IL137510A0 (en) 2001-07-24
KR100991683B1 (ko) 2010-11-04
DE69936948T2 (de) 2008-05-15
EP1054955A2 (de) 2000-11-29
EP1741777A1 (de) 2007-01-10
ATE371020T1 (de) 2007-09-15
KR20080065615A (ko) 2008-07-14
KR20090038927A (ko) 2009-04-21
EP1526173A2 (de) 2005-04-27
EP1526174B1 (de) 2007-08-22
PL342847A1 (en) 2001-07-16
JP2010213727A (ja) 2010-09-30
EP1526173A3 (de) 2005-08-10
AR020054A1 (es) 2002-04-10
BR9908015A (pt) 2001-04-24
ES2272053T3 (es) 2007-04-16
EP1526174A2 (de) 2005-04-27
HU226015B1 (en) 2008-02-28
ATE341614T1 (de) 2006-10-15
KR100912362B1 (ko) 2009-08-19
TWI232107B (en) 2005-05-11
DE69936948D1 (de) 2007-10-04
SK11842000A3 (sk) 2001-05-10
EP1054955B1 (de) 2006-10-04
PT1054955E (pt) 2007-01-31
CN101164623A (zh) 2008-04-23
NO20004104L (no) 2000-10-17
PE20000265A1 (es) 2000-04-25
ATE478945T1 (de) 2010-09-15
KR100918187B1 (ko) 2009-09-22
HK1097413A1 (en) 2007-06-22
HK1073481A1 (en) 2005-10-07
AU2653899A (en) 1999-08-30
EP1526173B1 (de) 2012-11-21
JP2002503484A (ja) 2002-02-05
PL197747B1 (pl) 2008-04-30
DE69933433D1 (de) 2006-11-16
HK1028416A1 (en) 2001-02-16
JP2006166925A (ja) 2006-06-29
CN100374551C (zh) 2008-03-12
CA2320419C (en) 2011-02-08
KR20090127947A (ko) 2009-12-14
AR063314A2 (es) 2009-01-21
NO20004104D0 (no) 2000-08-16
AR063315A2 (es) 2009-01-21
AU757976B2 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
DE69936948D1 (de) Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
ATE363904T1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
DE69837703D1 (de) Methoden zum nachweis und zur analyse von virus
DE69935345D1 (de) Methoden und zusammensetzungen zur prävention und behandlung der anämie
DE19882430T1 (de) Korrektur von Emissions-Kontamination und Totzeitverlust
DE60035497D1 (de) Verfharen zur konservierung von viren und mycoplasma
DE69838728D1 (de) Methoden und zusammensetzungen zum wirksameren abfangen von sauerstoff
DE69925820D1 (de) Zubereitungen zur stabilisierung von peg-interferon alpha konjugaten
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE29808006U1 (de) Sprühvorrichtung zur Behandlung von Schnitt- und Fräskanten
DE60006412D1 (de) Oxazinochinolone zur behandlung von viralen infektionen
DE69002558D1 (de) Zusammensetzungen und methoden zur verhinderung von inkrustierungen.
DE69821053D1 (de) Verfahren zur Herstellung von 2,2,6,6-Tetramethyl-4-piperidyl-Gruppen enthaltenden Polytriazinen
DE59905059D1 (de) Verfahren zur Herstellung von Hydroxyethylcyclohexanen und Hydroxyethylpiperidinen
ATE295182T1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
DE69428610D1 (de) Methoden zur kultivierung von infektiösem laryngotracheitis virus und von "egg-drop-syndrome" verursachendem virus
ATA4812000A (de) Mittel zur behandlung von hepatitis c
DE19681235D2 (de) Verfahren zur Deaktivierung der HIV und anderer Viren
ATE255594T1 (de) Hepatitis b inhibitoren
DE59813114D1 (de) BK-RiV-Präparate zur Behandlung von proliferativen Zellerkrangungen
DE60008697D1 (de) Verfahren zur Herstellung von 4-(P-methoxyphenyl)-2-amino-butane und Insektizide
DE60114532D1 (de) Verfahren zur Herstellung von optisch activem 1H-3-Aminopyrrolidin und Derivaten davon
DE69833655D1 (de) Methoden und zusammensetzungen zur behandlung der hyperlipidämie
PT841943E (pt) Virus herpeticos avirulentos uteis como agentes tumoricidas e vacinas
ZA991235B (en) Compositions comprising viruses and methods for concentrating virus preparations.